The effect of some decarboxylase inhibitors on striatal tyramines in the mouse.
The administration of carbidopa (5-50 mg/kg), a peripheral L-aromatic aminoacid decarboxylase inhibitor, significantly increased striatal tyramines; maximal effects were observed at 2-4 hr after treatment. Benserazide produced similar effects. The drug, NSD 1034, that inhibits both central and peripheral decarboxylase, produced a dose-dependent reduction in striatal p-tyramine; in contrast, concentrations of m-tyramine were increased by the smaller doses (2-20 mg/kg) and reduced by the larger dose (400 mg/kg). The results support the view that the tyramines are formed within the brain by decarboxylation of their parent aminoacids but by different mechanisms.
D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001545:Benserazide / Q000494:pharmacology; D002230:Carbidopa / Q000494:pharmacology*; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D006834:Hydrazines / Q000494:pharmacology; D007536:Isomerism; D008297:Male; D051379:Mice; D014439:Tyramine / Q000378:metabolism*
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D006834:Hydrazines; C020173:NSD 1034; D001545:Benserazide; D002262:Carboxy-Lyases; D002230:Carbidopa; D014439:Tyramine